Publication: Urinary proteomics revealed prostaglandin H<inf>2</inf>D-isomerase, not Zn-α2-glycoprotein, as a biomarker for active lupus nephritis
Issued Date
2012-06-18
Resource Type
ISSN
18767737
18743919
18743919
Other identifier(s)
2-s2.0-84861717304
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of Proteomics. Vol.75, No.11 (2012), 3240-3247
Suggested Citation
Poorichaya Somparn, Nattiya Hirankarn, Asada Leelahavanichkul, Weerapan Khovidhunkit, Visith Thongboonkerd, Yingyos Avihingsanon Urinary proteomics revealed prostaglandin H<inf>2</inf>D-isomerase, not Zn-α2-glycoprotein, as a biomarker for active lupus nephritis. Journal of Proteomics. Vol.75, No.11 (2012), 3240-3247. doi:10.1016/j.jprot.2012.03.034 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/13698
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Urinary proteomics revealed prostaglandin H<inf>2</inf>D-isomerase, not Zn-α2-glycoprotein, as a biomarker for active lupus nephritis
Abstract
Although renal histopathology is the gold standard for the diagnosis and prognosis of lupus nephritis (LN), the invasiveness of renal biopsy warrants the discovery of novel non-invasive diagnostic and prognostic biomarkers. In the present study, urine samples from 10 LN patients (5 active and 5 inactive) were analyzed by two-dimensional gel electrophoresis (2-DE) to screen for potential biomarkers of active LN. Quantitative analysis and statistics revealed 16 protein spots whose levels significantly differed between groups. These proteins were successfully identified by electrospray ionization quadrupole time-of-flight tandem mass spectrometry (ESI-Q-TOF MS/MS). Among these potential candidates, differential levels of urinary Zn-α2-glycoprotein (ZA2G) and prostaglandin H 2 D-isomerase (PGDS) were further validated by enzyme-linked immunosorbent assay (ELISA) in another independent group of 78 subjects, including 30 active LN, 26 inactive LN, 14 non-LN glomerular diseases, and 8 healthy normal individuals. Whereas ZA2G levels were elevated in urine of patients with active LN and non-LN glomerular diseases, PGDS was elevated only in the urine of the active LN group. Urinary PGDS, not ZA2G, may serve as a biomarker for active LN and upon validation in larger studies, may become the non-invasive test to evaluate the disease activity in future management of LN. © 2012 Elsevier B.V.